Effective anti-adhesives of uropathogenic Escherichia coli

Open access

Abstract

Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC) are among the most common infectious diseases in humans. Due to their frequent occurrence in the community and nosocomial settings, as well as the development of resistance to the commonly prescribed antimicrobial agents, an enormous financial burden is placed on healthcare systems around the world. Therefore, novel approaches to the prevention and treatment of UTIs are needed. Although UPEC may harbour a plethora of virulence factors, type I fimbriae and P pili are two of the most studied adhesive organelles, since the attachment to host cells in the urinary tract is a crucial step towards infection. Design of receptor analogues that competitively bind to UPEC surface adhesins placed at the top of pili organelles led to the development of anti-adhesive drugs that are increasingly recognized as important and promising alternatives to antibiotic treatment of UTIs.

References

  • 1. B. Foxman, Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden, Infect. Dis. Clin. North Am. 28 (2014) 1-13; https://doi.org/10.1016/j.idc.2013.09.003

  • 2. K. Gupta, T. M. Hooton and W. E. Stamm, Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections, Ann. Intern. Med. 135 (2001) 41-50; https://doi.org/10.7326/0003-4819-135-1-200107030-00012

  • 3. M. G. Blango and M. A. Mulvey, Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics, Antimicrob. Agents Chemother. 54 (2010) 1855-1863; https://doi.org/10.1128/AAC.00014-10

  • 4. C. Aypak, A. Altunsoy and N. Düzgün, Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: A prospective observational study, Ann. Clin. Microbiol. Antimicrob. 8 (2009) Article ID 27; https://doi.org/10.1186/1476-0711-8-27

  • 5. J. A. Karlowsky, D. J. Hoban, M. R. Decorby, N. M. Laing and G. G. Zhanel, Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: Results from the North American urinary tract infection collaborative alliance-quinolone resistance study, Antimicrob. Agents Chemother. 50 (2006) 2251-2254; https://doi.org/10.1128/AAC.00123-06

  • 6. D. Scholes, T. M. Hooton, P. L. Roberts, K. Gupta, A. E. Stapleton and W. E. Stamm, Risk factors with acute pyelonephritis in healthy women, Ann. Intern. Med. 142 (2005) 20-27; https://doi.org/10.7326/0003-4819-142-1-200501040-00008

  • 7. T. J. Hannan, I. U. Mysorekar, C. S. Hung, M. L. Isaacson-Schmid and S. J. Hultgren, Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection, PLoS Pathog. 6 (2010) e1001042; https://doi.org/10.1371/journal.ppat.1001042

  • 8. D. J. Schwartz, S. L. Chen, S. J. Hultgren and P. C. Seed, Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection, Infect. Immun. 79 (2011) 4250-4259; https://doi.org/10.1128/IAI.05339-11

  • 9. L. Nicolle, Complicated urinary tract infection in adults, Can. J. Infect. Dis. Med. Microbiol. 16 (2005) 349-360; https://doi.org/10.1155/2005/385768

  • 10. T. J. Wiles, R. R. Kulesus and M. A. Mulvey, Origins and virulence mechanisms of uropathogenic Escherichia coli, Exp. Mol. Pathol. 85 (2008) 11-19; https://doi.org/10.1016/j.yexmp.2008.03.007

  • 11. R. J. Doyle, Contribution of the hydrophobic effect to microbial infection, Microb. Infect. 2 (2000) 391-400; https://doi.org/10.1016/S1286-4579(00)00328-2

  • 12. J. W. Costerton, P. S. Stewart and E. P. Greenberg, Bacterial biofilms: a common cause of persistent infections, Science 284 (1999) 1318-1322; https://doi.org/10.1126/science.284.5418.1318

  • 13. H. Connell, W. Agace, P. Klemm, M. Schembri, S. Marild and C. Svanbord, Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract, Proc. Natl. Acad. Sci. USA 93 (1996) 9827-9832.

  • 14. A. J. Lewis, A. C. Richards and M. A. Mulvey, Invasion of host cells and tissues by uropathogenic bacteria, Microb. Spectr. 4 (2016) UTI-0026-2016 (29 pages); https://doi.org/10.1128/microbiolspec.UTI-0026-2016

  • 15. M. A. Mulvey, Y. S. Lopez-Boado, C. L. Wilson, R. Roth, W. C. Parks, J. Heuser and S. J. Hultgren, Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli, Science 282 (1998) 1494-1497; https://doi.org/10.1126/science.282.5393.1494

  • 16. J. J. Martinez, M. A. Mulvey, J. D. Schilling, J. S. Pinkner and S. J. Hultgren, Type1 pilus-mediated bacterial invasion of bladder epithelial cells, EMBO J. 19 (2000) 2803-2812; https://doi.org/10.1093/emboj/19.12.2803

  • 17. M. Hartmann and T. K. Lindhorst, The bacterial lectin FimH, a target for drug discovery - carbohydrate inhibitors of type 1 fimbriae-mediated bacterial adhesion, Eur. J. Org. Chem. 2011 (2011) 3583-3609; https://doi.org/10.1002/ejoc.201100407

  • 18. G. G. Anderson, J. J. Palermo, J. D. Schilling, R. Roth, J. Heuser and S. J. Hultgren, Intracellular bacterial biofilm-like pods in urinary tract infections, Science 301 (2003) 105-107; https://doi.org/10.1126/science.1084550

  • 19. X. R. Wu, T. T. Sun and J. J. Medina, In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: Relation to urinary tract infections, Proc. Natl. Acad. Sci. USA 93 (1996) 9630-9635.

  • 20. J. A. Snyder, A. L. Lloyd, C. V. Lockatell, D. E. Johnson and H. L. Mobley, Role of phase variation of type 1 fimbriae in a uropathogenic Escherichia coli cystitis isolate during urinary tract infection, Infect. Immun. 74 (2006) 1387-1393; https://doi.org/10.1128/IAI.74.2.1387-1393.2006

  • 21. D. S. Eto, T. A. Jones, J. L. Sundsbak and M. M. Mulvey, Integrin-mediated host cell invasion by type 1-piliated uropathogenic Escherichia coli, PLoS Pathog. 3 (2007) e100; https://doi.org/10.1371/journal.ppat.0030100

  • 22. J. Song, B. L. Bishop, G. Li, R. Grady, A. Stapleton and S. N. Abraham, TLR4-mediated expulsion of bacteria from infected bladder epithelial cells, Proc. Natl. Acad. Sci. USA 106 (2009) 14966-14971; https://doi.org/10.1073/pnas.0900527106

  • 23. P. Thumbikat, R. E. Berry, G. Zhou, B. K. Billips, R. E. Yaggie, T. Zaichuk, T. T. Sun, A. J. Schaeffer and D. J. Klumpp, Bacteria-induced uroplakin signaling mediates bladder response to infection, PLoS Pathog. 5 (2009) e1000415; https://doi.org/10.1371/journal.ppat.1000415

  • 24. L. S. Ronald, O. Yakovenko, N. Yazvenko, S. Chattopadhyay, P. Aprikian, W. E. Thomas and E. V. Sokurenko, Adaptive mutations in the signal peptide of the type1fimbrial adhesin of uropathogenic Escherichia coli, Proc. Natl. Acad. Sci. USA 105 (2008) 10937-10942; https://doi.org/10.1073/pnas.0803158105

  • 25. S. L. Chen, C. S. Hung, J. S. Pinkner, J. N. Walker, C. K. Cusumano, Z. Li, J. Bouckaert, J. I. Gordon and S. L. Hultgren. Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding, Proc. Natl. Acad. Sci. USA 106 (2009) 22439-22444; https://doi.org/10.1073/pnas.0902179106

  • 26. D. Choudhury, A. Thompson, V. Stojanoff, S. Langermann, J. Pinkner, S. J. Hultgren and S. D. Knight, X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli, Science 285 (1999) 1061-1066; https://doi.org/10.1126/science.285.5430.1061

  • 27. C. S. Hung, J. Bouckaert, D. Hung, J. Pinkner, C. Widberg, A. DeFusco, C. G. Auguste, R. Strouse, S. Langermann, G. Waksman and S. J. Hultgren, Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection, Mol. Microbiol. 44 (2002) 903-915; https://doi.org/10.1046/j.1365-2958.2002.02915.x

  • 28. J. Bouckaert, J. Berglund, M. Schembri, E. De Genst, L. Cools, M. Wuhrer, C. S. Hung, J. Pinkner, R. Slättegård, A. Zavialov, D. Choudhury, S. Langermann, S. J. Hultgren, L. Wyns, P. Klemm, S. Oscarson, S. D. Knight and H. De Greve, Receptor binding studies disclose a novel class of highaffinity inhibitors of the Escherichia coli FimH adhesin, Mol. Microbiol. 55 (2005) 441-455; https://doi.org/10.1111/j.1365-2958.2004.04415.x

  • 29. S. J. Hultgren, F. Lindberg, G. Magnusson, J. Kihlbergt, J. M. Tennent and S. Normark, The PapG adhesin of uropathogenic Escherichia coli contains separate regions for receptor binding and for the incorporation into the pilus, Proc. Nat. Acad. Sci. USA 86 (1989) 4357-4361.

  • 30. F. K. de Graaf and F. R. Mooi, The fimbrial adhesins of Escherichia coli, Adv. Microb. Physiol. 28 (1986) 65-143.

  • 31. G. Bergsten, B. Wullt and C. Svanborg, Echerichia coli, fimbriae, bacterial persistence and host response induction in the human urinary tract, Int. J. Med. Microbiol. 295 (2005) 487-502; https://doi.org/10.1016/j.ijmm.2005.07.008

  • 32. K. W. Dodson, J. S. Pinkner, T. Rose, G. Magnusson, S. J. Hultgren and G. Waksman, Structural basis of the interaction of the pyelonephritic E. coli adheson of its human kidney receptor, Cell 105 (2001) 733-743; https://doi.org/10.1016/S0092-8674(01)00388-9

  • 33. J. Bien, O. Sokolova and P. Bozko, Role of uropathogenic Escherichia coli virulence factors in development of urinary tract infection and kidney damage, Int. J. Nephrol. 2012 (2012) Article ID 681473; https://doi.org/10.1155/2012/681473

  • 34. U. Dobrindt, G. Blum-Oehler, T. Hartsch, G. Gottschalk, E. Z. Ron, R. Fünfstück and J. Hacker, S-fimbria-encoding determinant sfa(I) is located on pathogenicity island III(536) of uropathogenic Escherichia coli strain 536, Infect. Immun. 69 (2001) 4248-4256; https://doi.org/10.1128/IAI.69.7.4248-4256.2001

  • 35. T. K. Korhonen, V. Väisänen-Rhen, M. Rhen, A. Pere, J. Parkkinen and J. Finne, Escherichia coli fimbriae recognizing sialyl galactosides, J. Bacteriol. 159 (1984) 762-766.

  • 36. A. S. Khan, I. Mühldorfer, V. Demuth, U. Wallner, T. K. Korhonen and J. Hacker, Functional analysis of the minor subunits of S fimbrial adhesion (SfaI) in pathogenic Escherichia coli, Mol. Gen. Genet. 263 (2000) 96-105; https://doi.org/10.1007/PL00008680

  • 37. M. Castelain, S. Ehlers, J. Klinth, S. Lindberg, M. Andersson, B. E. Uhlin and O. Axner, Fast uncoiling kinetics of F1C pili expressed by uropathogenic Escherichia coli are revealed on a single pilus level using force-measuring optical tweezers, Eur. Biophys. J. 40 ( 2011) 3 05-316; https://doi.org/10.1007/s00249-010-0648-1

  • 38. F. Backhed, B. Alsen, N. Roche, J. Angstrom, A. von Euler, M. E. Breimer, B. Westerlund-Wikstrom, S. Teneberg and A. Richter-Dahlfors, Identification of target tissue glycosphingolipid receptors for uropathogenic, F1C-fimbriated Escherichia coli and its role in mucosal inflammation, J. Biol. Chem. 227 (2002) 18198-18205; https://doi.org/10.1074/jbc.M111640200

  • 39. A. S. Khan, B. Kniep, T. A. Oelschlaeger, I. Van Die, T. Korhonen and J. Hacker, Receptor structure for F1C fimbriae of uropathogenic Escherichia coli, Infect. Immun. 68 (2000) 3541-3547; https://doi.org/10.1128/IAI.68.6.3541-3547.2000

  • 40. N. Riegman, H. Hoschützky, I. van Die, W. Hoekstra, K. Jann and H. Bergmans, Immunocytochemical analysis of P-fimbrial structure: localization of minor subunits and the influence of the minor subunit FsoE on the biogenesis of the adhesin, Mol. Microbiol. 4 (1990) 1193-1198; https://doi.org/10.1111/j.1365-2958.1990.tb00694.x

  • 41. E. M. Antão, L. H. Wieler and C. Ewers, Adhesive threads of extraintestinal pathogenic Escherichia coli, Gut Pathog. 1 (2009) Article ID 22; https://doi.org/10.1186/1757-4749-1-22

  • 42. T. K. Lindhorst, C. Kieburg and U. Krallmann-Wenzel, Inhibition of the type 1 fimbriae-mediated adhesion of Escherichia coli to erythrocytes by multiantennary alpha-mannosyl clusters: the effect of multivalency, Glycoconjugate J. 15 (1998) 605-613; https://doi.org/10.1023/A:1006920027641

  • 43. T. K. Lindhorst, S. Kötter, U. Krallmann-Wenzel and S. Ehlers, Trivalent α-d-mannoside clusters as inhibitors of type-1 fimbriae-mediated adhesion of Escherichia coli: structural variation and biotinylation, J. Chem. Soc. Perkin Trans. 1 8 (2001) 823-831; https://doi.org/10.1039/B009786L

  • 44. C. Heidecke and T. K. Lindhorst, Iterative synthesis of spacered glycodendrons as oligomannoside mimetics and evaluation of their antiadhesive properties, Chem. Eur. J. 13 (2007) 9056-9067; https://doi.org/10.1002/chem.200700787

  • 45. M. Touaibia, A. Wellens, T. C. Shiao, Q. Wang, S. Sirois, J. Bouckaert and R. Roy, Mannosylated G(0) dendrimers with nanomolar affinities to Escherichia coli FimH, ChemMedChem 2 (2007) 1190-1201; https://doi.org/10.1002/cmdc.200700063

  • 46. O. Schwardt, S. Rabbani, M. Hartmann, D. Abgottspon, M. Wittwer, S. Kleeb, A. Zalewski, M. Smieško, B. Cutting and B. Ernst, Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists, Bioorg. Med. Chem. 19 (2011) 6454-6473; https://doi.org/10.1016/j.bmc.2011.08.057

  • 47. N. Nagahori, R. T. Lee, S. I. Nishimura, D. Pagé, R. Roy and Y. C. Lee, Inhibition of adhesion of type 1 fimbriated Escherichia coli to highly mannosylated ligands, ChemBioChem 3 (2002) 836-844; https://doi.org/10.1002/1439-7633(20020902)3:9<836::AID-CBIC836>3.0.CO;2-2

  • 48. M. Dubber, O. Sperling and T. K. Lindhorst, Oligomannoside mimetics by glycosylation of ‘octopus glycosides’ and their investigation as inhibitors of type 1 fimbriae-mediated adhesion of Escherichia coli, Org. Biomol. Chem. 4 (2006) 3901-3912; https://doi.org/10.1039/B610741A

  • 49. Z. Han, J. S. Pinkner, B. Ford, R. Obermann, W. Nolan S. A Wildman, D. Hobbs, T. Ellenberger, K. Cusumano, S. J. Hultgren and J. W. Janetka, Structure-based drug design and optimization of mannoside bacterial FimH antagonists, J. Med. Chem. 53 (2010) 4779-4792; https://doi.org/10.1021/jm100438s

  • 50. A. Wellens, C. Garofalo, H. Nguyen, N. VanGerven, R. Slättegård, J. P. Hernalsteens, L. Wyns, S. Oscarson, H. DeGreve, S. Hultgren and J. Bouckaert, Intervening with urinary tract infections using anti-adhesives based on the crystal structure of theFimH-oligomannose-3 complex, PLoS One 3 (2008) e2040; https://doi.org/10.1371/journal.pone.0002040

  • 51. R. Ribić, M. Kovačević, V. Petrović-Peroković, I. Gruić-Sovulj, V. Rapić and S. Tomić, Synthesis and biological activity of mannose conjugates with 1-adamantamine and ferrocene amines, Croat. Chem. Acta 83 (2010) 421-431.

  • 52. M. Kovačević, L. Barišić, R. Ribić, V. Petrović Peroković, S. Tomić and V. Rapić, Ferrocene conjugates with mannose: synthesis and influence of ferrocene aglycon on mannose-mediated adhesion of Escherichia coli, Appl. Organometal. Chem. 26 (2012) 74-79; https://doi.org/10.1002/aoc.1869

  • 53. V. Kovač, R. Ribić, V. Petrović Peroković, S. Tomić and L. Barišić, Synthesis, spectral characterization and inhibitory potency of ferrocene-containing mannosides towards type 1 fimbriated Escherichia coli, Appl. Organometal. Chem. 30 (2013) 524-530; https://doi.org/10.1002/aoc.3465

  • 54. T. K. Lindhorst, S. Kötter, J. Kubisch, U. Krallmann-Wenzel, S. Ehlers and V. Křen, Effect of psubstitution of aryl α-d-mannosides on inhibiting mannose-sensitive adhesion of Escherichia coli - syntheses and testing, Eur. J. Org. Chem. 1998 (1998) 1669-1674; https://doi.org/10.1002/(SICI)1099-0690(199808)1998:8<1669::AID-EJOC1669>3.0.CO;2-Q

  • 55. N. Firon, S. Ashkenazi, D. Mirelman, I. Ofek and N. Sharon, Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast a find intestinal epithelial cells, Infect. Immun. 55 (1987) 472-476.

  • 56. O. Sperling, A. Fucha and T. K. Lindhorst, Evaluation of the carbohydrate recognition domain of the bacterial adhesin FimH: design, synthesis and binding properties of mannoside ligands, Org. Biomol. Chem. 4 (2006) 3913-3922; https://doi.org/10.1039/b610745a

  • 57. Ž. Car, T. Hrenar, V. Petrović Peroković, R. Ribić, M. Seničar and S. Tomić, Mannosylated N-aryl substituted 3-hydroxypyridine-4-ones: synthesis, hemagglutination inhibitory properties, and molecular modeling, Chem. Biol. Drug Des. 84 (2014) 393-401; https://doi.org/10.1111/cbdd.12329

  • 58. V. Petrović Peroković, R. Ribić, Ž. Car and S. Tomić, Comparison of inhibitory activities of meta and para substituted N-aryl 3-hydroxypyridin-4-one mannosides towards type 1 fimbriated E. coli, Croat. Chem. Acta 89 (2016) 237-242; https://doi.org/10.5562/cca2890

  • 59. S. Kleeb, X. Jiang, P. Frei, A. Sigl, J. Bezençon, K. Bamberger, O. Schwardt and B. Ernst, FimH antagonists: Phosphate prodrugs improve oral bioavailability, J. Med. Chem. 59 (2016) 3163-3182; https://doi.org/10.1021/acs.jmedchem.5b01923

  • 60. S. Kleeb, L. Pang, K. Mayer, D. Eris, A. Sigl, R. C. Preston, P. Zihlmann, T. Sharpe, R. P. Jakob, D. Abgottspon, A. S. Hutter, M. Scharenberg, X. Jiang, G. Navarra, S. Rabbani, M. Smiesko, N. Lüdin, J. Bezençon, O. Schwardt, T. Maier and B. Ernst, FimH antagonists: Bioisosteres to improve the in vitro and in vivo PK/PD profile, J. Med. Chem. 58 (2015) 2221-2239; https://doi.org/10.1021/jm501524q

  • 61. K. L. LaPlante, S. A. Sarkisian, S. Woodmansee, D. C. Rowley and N. P. Seeram, Effects of cranberry extracts on growth and biofilm production of Escherichia coli and Staphylococcus species, Phytother. Res. 26 (2012) 1371-1374; https://doi.org/10.1002/ptr.4592

  • 62. A. Gupta, M. Dwivedi, A. A. Mahdi, G. A. Nagana Gowda, C. L. Khetrapal and M. Bhandari, Inhibition of adherence of multi-drug resistant E. coli by proanthocyanidin, Urol. Res. 40 (2012) 143-150; https://doi.org/10.1007/s00240-011-0398-2

  • 63. A. B. Howell, J. D. Reed, C. G. Krueger, R. Winterbottom, D. G. Cunningham and M. Leahy, A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity, Phytochemistry 66 (2005) 2281-2291; https://doi.org/10.1016/j.phytochem.2005.05.022

  • 64. J. Sun, J. P. J. Marais, C. Khoo, K. LaPlante, R. M. Vejborg, M. Givskov, T. Tolker-Nielsen, N. P. Seeram and D. C. Rowley, Cranberry (Vaccinium macrocarpon) oligosaccharides decrease biofilm formation by uropathogenic Escherichia coli, J. Funct. Foods 17 (2015) 235-242; https://doi.org/10.1016/j.jff.2015.05.016

  • 65. E. Papas and K. M. Schaich, Phytochemicals of cranberries and cranberry products: Characterization, potential health effects and processing stability, Crit. Rev. Food Sci. Nutr. 49 (2009) 741-781; https://doi.org/10.1080/10408390802145377

  • 66. D. G. de Llano, A. Esteban-Fernández, F. Sánchez-Patán, P. J. Martínlvarez, M. V. Moreno-Arribas and B. Bartolomé, Anti-adhesive activity of cranberry phenolic compounds and their microbialderived metabolites against uropathogenic Escherichia coli in bladder epithelial cell cultures, Int. J. Mol. Sci. 16 (2015) 12119-12130; https://doi.org/10.3390/ijms160612119

  • 67. R. P. Felician, C. G. Krueger and J. D. Reed, Methods to determine effects of cranberry proanthocyanidins on extraintestinal infections: Relevance for urinary tract health, Mol. Nutr. Food Res. 59 (2015) 1292-1306; https://doi.org/10.1002/mnfr.201500108

  • 68. R. Rajbhandari, N. Peng, R. Moore, A. Arabshahi, J. M. Wyss, S. Barnes and J. K. Prasain, Determination of cranberry phenolic metabolites in rats by liquid chromatography-tandem mass spectrometry, J. Agric. Food Chem. 59 (2011) 6682-6688; https://doi.org/10.1021/jf200673h

  • 69. A. B. Howell, H. Botto, C. Combescure, A.-B. Blanc-Potard, L. Gausa, T. Matsumoto, P. Tenke, A. Sotto and J.-P. Lavigne, Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study, BMC Infect. Dis. 10 (2010) Article ID 94; https://doi.org/10.1186/1471-2334-10-94

  • 70. L. Y. Foo, Y. Lu, A. B. Howell and N. Vorsa, A-type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated Escherichia coli, J. Nat. Prod. 63 (2000) 1225-1228; https://doi.org/10.1021/np000128u

  • 71. D. L. McKay, C. Y. Chen, C. A. Zampariello and J. B. Blumberg, Flavonoids and phenolic acids from cranberry juice are bioavailable and bioactive in healthy older adults, Food Chem. 168 (2015) 233-240; https://doi.org/10.1016/j.foodchem.2014.07.062

  • 72. K. Valentova, D. Stejskal, P. Bednar, J. Vostalova, C. Cíhalík, R. Vecerova, D. Koukalova, M. Kolar, R. Reichenbach. L. Sknouril, J. Ulrichova and V. Simanek, Biosafety, antioxidant status, and metabolites in urine after consumption of dried cranberry juice in healthy women: a pilot doubleblind placebo-controlled trial, J. Agric. Food Chem. 55 (2007) 3217-3224; https://doi.org/10.1021/jf0636014

  • 73. C. Wang, Y. Zuo, J. A. Vinson and Y. Deng, Absorption and excretion of cranberry-derived phenolics in humans, Food Chem. 132 (2012) 1420-1428; https://doi.org/10.1016/j.foodchem.2011.11.131

  • 74. M. A. Polewski, C. G. Krueger, J. D. Reed and G. Leyer, Ability of cranberry proanthocyanidins in combination with a probiotic formulation to inhibit in vitro invasion of gut epithelial cells by extra-intestinal pathogenic E. coli, J. Funct. Foods 25 (2016) 123-134; https://doi.org/10.1016/j.jff.2016.05.015

  • 75. D. Nicolosi, G. Tempera, C. Genovese and P. M. Furneri, Anti-adhesion activity of A2-type proanthocyanidins (a cranberry major component) on uropathogenic E. coli and P. mirabilis strains, Antibiotics (Basel) 3 (2014) 143-154; https://doi.org/10.3390/antibiotics3020143

  • 76. M. A. Amalaradjou, A. Narayanan and K. Venkitanarayanan, Trans-cinnamaldehyde decreases attachment and invasion of uropathogenic Escherichia coli in urinary tract epithelial cells by modulating virulence gene expression, J. Urol. 185 (2011) 1526-1531; https://doi.org/10.1016/j.juro.2010.11.078

  • 77. A. E. Stapleton, J. Dziura, T. M. Hooton, M. E. Cox, Y. Yarova-Yarovaya, S. Chen and K. Gupta, Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial, Mayo Clin. Proc. 87 (2012) 143-150; https://doi.org/10.1016/j.mayocp.2011.10.006

  • 78. Â. Luís, F. Domingues and L. Pereira, Can cranberries contribute to reduce the incidence of urinary tract infections? - A systematic review with meta-analysis and trial sequential analysis of clinical trials, J. Urol. 198 (2017) 614-621; https://doi.org/10.1016/j.juro.2017.03.078

  • 79. R. Fumeaux, C. Menozzi-Smarrito, A. Stalmach, C. Munari, K. Kraehenbuehl, H. Steiling, A. Crozier, G. Williamson and D. Barron, First synthesis, characterization, and evidence for the presence of hydroxycinnamic acid sulfate and glucuronide conjugates in human biological fluids as a result of coffee consumption, Org. Biomol. Chem. 8 (2010) 5199-5211; https://doi.org/10.1039/c0ob00137f

  • 80. C. G. Krueger, J. D. Reed, R. P. Feliciano and A. B. Howell, Quantifying and characterizing proanthocyanidins in cranberries in relation to urinary tract health, Anal. Bioanal. Chem. 405 (2013) 4385-4395; https://doi.org/10.1007/s00216-013-6750-3

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information


IMPACT FACTOR 2016: 1.288
5-year IMPACT FACTOR: 1.600

CiteScore 2016: 1.55

SCImago Journal Rank (SJR) 2016: 0.353
Source Normalized Impact per Paper (SNIP) 2016: 0.854

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 38 38 38
PDF Downloads 17 17 17